Skip to main content

Table 2 Main adverse events reported in the included RCTs

From: Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials

Main adverse events No. of studies Immunosuppressive agent group Control group RR (95% CI) P value
FE RE FE RE
Gastrointestinal 11 38/431 8/606 2.53 [1.15, 5.55] 2.42[1.07, 5.45] 0.02 0.03
Hematologic 9 16/373 6/551 2.17 [1.00, 4.68] 2.0[0.84, 4.77] 0.05 0.12
Dermatologic 7 16/273 3/463 4.09 [1.57, 10.66] 3.88[1.41, 10.64] 0.004 0.009
Hepatotoxicity 7 21/455 19/636 1.26 [0.72, 2.22] 1.26[0.70, 2.24] 0.42 0.44
Respiratory 6 9/371 12/544 0.81 [0.37, 1.74] 0.82[0.37, 1.82] 0.58 0.62
Infection 6 189/373 114/547 Not estimable Not estimable Not estimable Not estimable
Impaired glucose tolerance or diabetes mellitus 5 15/326 5/316 2.61 [1.04, 6.55] 2.16[0.77, 6.05] 0.04 0.14
Elevation of blood pressure 4 14/193 16/389 0.96 [0.52, 1.79] 0.97[0.43, 2.22] 0.9 0.95
Malignant 4 4/167 2/157 1.40 [0.39, 4.98] 1.33[0.30, 5.93] 0.61 0.71
Musculoskeletal 3 5/238 3/226 1.47 [0.44, 4.93] 1.37[0.40, 4.71] 0.53 0.62
Hyperkalemia 3 2/156 11/350 0.23 [0.07, 0.71] 0.3[0.05, 1.98] 0.01 0.21
Genitourinary 3 6/59 0/56 4.59 [0.85, 24.85] 4.07[0.71, 23.39] 0.08 0.12
Death 2 3/218 2/206 1.42 [0.24, 8.44] 1.41 [0.23, 8.55] 0.70 0.71
  1. RR relative risk, CI confidence intervals, FE fixed effect model, RE random effect model